Indeed, PBMCs from AD patients at a moderate stage can induce a decrease expression of CCL2 and CCL5 in endothelial and abluminal compartments with also a decrease in PBMCs in the BBB model compared to PBMCs issued from patients with mild AD. The gene discussed is CCL2; the disease is Alzheimer disease.